Used Retinoids? Here's the Real Reason Your Eyes Have Never Felt Right Since.

After 23 years of clinical practice — and watching my own mother live with the same condition for 38 — I started noticing a pattern nobody in my field was talking about. Then the 2022 research confirmed it. Here's what I now tell every patient who's used retinoids — Accutane, prescription tretinoin, or daily retinol — and what gave the ones I'd nearly given up on their relief back.

For the first ten years of my career, I assumed dry eye was a condition of aging.

Most of my patients were over 50. Most were peri-menopausal women. Most responded — at least partially — to the standard protocol: drops, warm compresses, omega-3s, and if needed, prescriptions like Restasis.

Then I started getting a different kind of patient.

They were younger. Mostly in their 30s and 40s. Their eyes were worse than the 60-year-olds I was treating. And nothing in the standard protocol was touching them.

They'd come in and say things like "I haven't worn contacts in fifteen years." Or "I keep eye drops in three different places at home and I still wake up at 3am with my eyelids stuck shut." Or, in one memorable case from a woman in her late 30s:

I've had dry eyes for as long as I can remember being an adult. I forget what normal feels like.

I'd do their meibography — the scan that maps the oil glands in the eyelid — and the images would stop me cold.

These were 35-year-old eyes with the gland structure of 70-year-olds.

It took me longer than it should have to ask the right question. To be honest, the only reason I eventually asked it is because of my mother.

She took Accutane in 1987, for cystic acne, when I was in high school. By the time I was in optometry school, she was already complaining about her eyes "feeling wrong." By the time I opened my own practice, she'd given up contacts. By her late 50s, she carried preservative-free drops in every handbag she owned.

She is, now, one of the cases I describe in the rest of this article.

The Question I Started Asking Every New Patient

In 2017, I added two lines to my intake form. "Have you ever taken oral isotretinoin (Accutane, Roaccutane, Absorica, Claravis, or Sotret)?" And: "Have you used a topical retinoid — prescription tretinoin, tazarotene, adapalene, or any over-the-counter retinol product — for more than six months?"

The pattern emerged within six months.

My worst-responding patients — the ones whose dry eye looked decades older than they were, the ones who'd cycled through every drop and prescription with no relief — were overwhelmingly the patients who said yes to one or both of those questions.

Most of them had taken it once, in their teens or early twenties, for severe acne. Most had been told it was safe. Most had been warned about chapped lips and joint aches.

None of them had been warned about this.

My dermatologist mentioned dry eyes as a side effect that goes away when the course ends. That was 1998. They haven't gone away. They've gotten worse every decade. — A patient, 47, who first sat in my chair in 2019

If you're reading this and any of that sounds like your story — keep reading. Because what I'm about to share could finally explain why nothing has worked for you, and what I now tell every Accutane patient who walks through my door.

If Any of This Sounds Familiar, You're in the Right Place

Before I get into the science, let me ask you something.

If you checked even three of these — and you took Accutane at any point in your life — what I'm about to explain is almost certainly happening inside your eyelids right now.

What Retinoids Actually Do to Your Eyes (The Part Your Dermatologist Didn't Explain)

Here is what 25 years of research has now established, and what I wish every dermatologist would say to every patient before they wrote that prescription:

The meibomian glands in your eyelids are sebaceous glands.

Not similar to sebaceous glands. Not like sebaceous glands.

They are sebaceous glands. Specialized ones, embedded in your upper and lower eyelids, whose entire job is to produce the oil that prevents your tears from evaporating.

And isotretinoin's entire mechanism of action — the reason it works on severe acne — is that it systemically shuts down sebaceous gland function across your whole body.

It doesn't know the difference between the sebaceous glands clogging your face and the sebaceous glands lining your eyelids. It shuts both down. That's not a side effect. That's the drug doing exactly what it was designed to do — in the wrong location.

And here is what most patients don't know: topical retinoids do the same thing. The mechanism is identical — retinoic acid binding to receptors in sebaceous gland cells and shutting them down. The route is different. Oral isotretinoin reaches the meibomian glands through your bloodstream. Topical tretinoin and retinol reach them by migrating across the eyelid skin overnight, pooling in the warm crease above the lash line, and seeping into glands that sit just millimeters beneath. The damage is slower with topicals than with oral Accutane. But over four, six, ten years of nightly application, the damage compounds. The 2013 Ding study in Investigative Ophthalmology & Visual Science exposed cultured human meibomian gland cells to 13-cis retinoic acid in a petri dish and watched them die — and that is the exact same active ingredient that delivers from a topical cream into eyelid tissue, just at a lower dose, spread over more years.

Here's what the most recent research now shows:

• 30 to 50% of patients on systemic isotretinoin develop measurable dry eye symptoms during treatment (multiple studies summarized in Investigative Ophthalmology & Visual Science, 2022).
• By six months of treatment, patients show an average of 23.6% loss in upper meibomian gland structure and 20.7% loss in lower gland structure (Tanriverdi et al., 2022). To put that in context: a healthy 25-year-old should have lost zero percent.
• Isotretinoin disrupts the PPARγ signaling pathway in meibocytes — the very cells that produce the oil. This doesn't just reduce how much oil is produced. It changes what kind of oil is produced. Thicker. More viscous. Harder to flow through ducts that are simultaneously narrowing.
• For a meaningful subset of patients, these changes persist long after treatment ends. UC Berkeley's 12-month longitudinal study found that key metrics — number of expressed glands and meibum quality — remained altered six months post-therapy, with growing evidence of effects persisting for years or decades in some patients.

And here's the part nobody told you:

Over 13 million people have been treated with isotretinoin since 1982. A significant percentage of them are walking around right now with chronic, unexplained dry eye that started in their 20s and has compounded with every year of aging, screen time, and contact-lens wear since.

They don't know why. Most of their doctors don't know why.

Which leads to the question I get asked most often.

"Why Didn't My Doctor Tell Me About This?"

Three honest reasons.

First, the connection wasn't well-established when isotretinoin was first approved. The FDA's warning language has always been vague about ocular effects, mentioning "dry eyes" without specifying that the mechanism is permanent meibomian gland damage. Most dermatologists writing the prescription today still rely on the FDA monograph language.

Second, the time gap defeats attribution. If you took a six-month course in 1998 and developed noticeable symptoms in 2008, neither you nor your GP is going to connect the two events. Your dermatologist sees you for six months and discharges you. The damage shows up years later, in someone else's clinic.

Third — and this is the one most patients find hardest to hear — dry eye is a sub-specialty of optometry and ophthalmology. Most general ophthalmologists don't follow this literature any more closely than a general dermatologist follows oncology research. The protocols I'm describing here come from the dry eye sub-specialty community. They are not part of standard ophthalmology training.

If your eye doctor has never offered you anything beyond drops and "use a warm compress" — they're not negligent. They're a generalist treating a specialist condition.

Why Everything You've Tried Has Failed

When I sit down with a new Accutane patient and walk them through what's happening, the first thing they say is almost always: "So why hasn't anything worked?"

The answer is mechanical, not medical.

Eye drops

Drops add moisture to the surface of your eye. But your problem isn't that you're not making enough water. Your problem is that the oil that's supposed to seal the water in is too thick, too sluggish, or trapped in glands that can't release it. Drops evaporate in minutes because the seal is broken. You're refilling a bucket with no bottom.

Warm compresses and microwaveable masks (including the cheap $15 ones on Amazon)

Your eye doctor was right to recommend heat. Heat is the only at-home intervention that mechanically softens the thickened meibum that Accutane left behind. But here's the problem:

• Hardened meibum in MGD patients has a phase-transition temperature of approximately 40°C. It needs sustained heat at that temperature or above to liquefy.
• A microwaved washcloth drops below therapeutic temperature in 2–3 minutes.
• A Bruder mask or unbranded Amazon heated mask drops below it in 3–5 minutes — and dry heat dissipates roughly twice as fast as moist heat.
• The clinical minimum for effective gland therapy is 10 full minutes of sustained heat above 40°C.

You haven't been doing it wrong. The tool you were given was physically incapable of delivering what your glands needed.

LipiFlow

Around $1,100–$1,500 per session, not covered by most insurance. It works while you're in the chair because it sustains the heat. But the effects fade if you don't follow up with daily home maintenance — which, again, you couldn't deliver with a washcloth. A Cochrane review of 13 trials found "limited evidence of a clinically meaningful difference between LipiFlow and basic warm compresses" once you account for the lack of follow-up.

Restasis and Xiidra

These target inflammation in the tear glands. They do nothing for blocked oil glands. For your specific condition, they're treating the wrong organ. Restasis averages 1.8 out of 5 on patient review sites. Xiidra: 52% of reviews are negative.

This is the moment in the consultation where my patients usually go quiet. Because they realize, often for the first time, that twenty years of "nothing works for me" wasn't them being broken.

It was them being given the wrong tools.

The Cost Math Nobody Adds Up

Let me put this in numbers, because most of my long-term Accutane patients have never actually added up what they've spent.

The average dry eye patient spends $500 to $1,200 per year out of pocket — and that's the average. My Accutane patients routinely spend more, because their condition is worse:

For reference: a Beminda Steam Therapy Pro Eye Mask is $99.99. One-time. No subscriptions. No prescriptions. No office visits.

The Window You Don't Want to Miss

There's one more piece of research I need to share with you, because it's the part that changed my practice the most.

In 2025, a major review published in Frontiers in Medicine established something we'd long suspected: there is a strong positive correlation (r = 0.766) between the duration of meibomian gland disease and the degree of gland atrophy. In plainer English: the longer your glands stay blocked, the more of them die — and once they're gone, they don't come back.

For Accutane patients specifically, this is compounded by every passing year of aging, every additional hour of screen time, and every year of accumulated MGD on top of the original damage.

But — and this is the part I want you to hear — the glands that are still alive can be rescued.

Not all of them. The ones that have already atrophied are gone. But the glands that are dormant, blocked, and underproducing — and you have far more of those than you think — can resume function when the meibum sitting inside them is consistently melted and expressed.

The question isn't whether the damage is reversible. It's how much of it you still have time to address.

Every month you wait is a month more of accumulated obstruction, more inflammation, more lost ground. There is no scenario in which delaying makes the outcome better.

What I Started Recommending — And Why

I am, by training and by temperament, a deeply cautious clinician.

I do not casually recommend products to my patients. I recommend protocols, and I let them buy whatever delivers the protocol best.

So when a colleague mentioned a steam-based eye therapy device called Beminda to me about eighteen months ago, my first reaction was skepticism. The dry eye device space is full of overpriced gadgets with no clinical backing.

What changed my mind was the mechanism. Beminda is built around the one approach that actually addresses post-isotretinoin MGD: sustained moist steam at therapeutic temperature, delivered hands-free for the full clinical duration.

It maintains 42°C for the entire 10-minute session — the temperature window established by Borchman's 2019 infrared spectroscopy study as the threshold for melting MGD-affected meibum. The steam delivery method specifically — moist heat, not dry heat — is what a 2025 meta-analysis in Contact Lens and Anterior Eye identified as significantly superior to standard compresses for tear film stability (p = 0.005).

Think of the difference this way: holding your hand above a pot of boiling water versus holding a warm towel against your skin. The towel cools in minutes. The steam transfers heat continuously, at consistent temperature, and adds moisture instead of stripping it. That's why moist heat works on viscous meibum where dry heat fails.

This isn't a new mechanism. It's the same thermal principle behind the Blephasteam device used in clinical settings for over a decade. Beminda made it accessible at home.

And before anyone asks me — yes, it's safe. Steam-based eyelid warming has been studied across 58 clinical trials with zero adverse events reported in the moisture-chamber device category. It runs at body-warmth temperatures. It's the same gentle warmth your dermatologist or rheumatologist would recommend if you asked them.

I started recommending it to my most difficult cases first. The Accutane patients. The ones I'd nearly run out of things to try with. Including, eventually, my mother.

What happened over the following six months changed how I practice.

What Happened With My Patients

I want to be honest about what to expect, because this audience has been promised miracle cures before and rightly distrusts them.

Week 1–2

Most patients report that their morning eyelid-stickiness reduces. The "sealed shut" sensation eases. Drop usage doesn't drop yet. This is the gland clearance phase — your glands are starting to express oil that's been trapped for years.

Week 3–6

This is when the real shift happens. Patients begin reducing their drop frequency. Several of my long-term Accutane patients have told me they went 24 hours without remembering to use drops for the first time in over a decade. Vision becomes more stable across the day.

Week 8–12

Several of my patients have re-attempted contact lenses for the first time in 10+ years and tolerated them for full workdays. Their meibography scans, while not back to "normal" (the structural damage from Accutane doesn't fully reverse), show measurably improved function in the glands they still have.

A few of their own words, with permission:

Why I'm Writing This

I'll close with what I tell every Accutane patient who walks into my clinic for the first time.

You are not broken. You were given a drug that did exactly what it was designed to do, in a place nobody warned you it would go. The damage is real, but it is not as final as you've been led to believe. There is a specific, mechanism-targeted protocol that addresses your exact condition. And it does not require a $1,500 in-office procedure to deliver.

If you took Accutane in your teens or twenties — and your eyes have been off ever since — please don't make peace with it for another decade.

You have more glands left than you think. The window to rescue them is still open.

But it is not open forever.